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Abstract: Neopterin has been extensively used as a clinical marker of immune activation during
inflammation in a wide range of conditions and stresses. However, the analysis of neopterin alone
neglects the cellular reactions that generate it in response to interferon-γ. Neopterin is the oxidation
product of 7,8-dihydroneopterin, which is a potent antioxidant generated by interferon-γ-activated
macrophages. 7,8-Dihydroneopterin can protect macrophage cells from a range of oxidants through a
scavenging reaction that generates either neopterin or dihydroxanthopterin, depending on the
oxidant. Therefore, plasma and urinary neopterin levels are dependent on both macrophage
activation to generate 7,8-dihydroneopterin and subsequent oxidation to neopterin. This relationship
is clearly shown in studies of exercise and impact-induced injury during intense contact sport. Here,
we argue that neopterin and total neopterin, which is the combined value of 7,8-dihydroneopterin
and neopterin, could provide a more comprehensive analysis of clinical inflammation than
neopterin alone.
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1. Introduction to Neopterin and 7,8-Dihydroneopterin
The level of clinical inflammation occurring as a result of physical trauma, cardiovascular
disease, cancer, bacterial, parasitic infections, and viral infections is often assessed by measuring
the concentration of plasma and urinary neopterin [1–5]. Neopterin analysis is used as the primary
screen of blood donations in Australia as an indicator for safe blood transfusion [6]. Our own research
group has made extensive use of neopterin analysis to assess exercise-induced injury and oxidative
stress during in vitro cell culture [7–9]. The reason for neopterin’s popularity is threefold: neopterin is
generated in response to γ-interferon activation of monocytes and macrophages, thus, it is a direct
product of immune system activation [10,11]; neopterin is highly fluorescent, and thus easily detected
at low concentration by HPLC [12,13]; there is a readily available ELISA-based assay for clinical
use [14]. The rapid clearance of neopterinby the kidneys [15] also makes urinary neopterin a reliable
measure of a person’s inflammatory state [9,16,17].
The convenience of measuring neopterin ignores the basic biology that macrophages do not
enzymatically synthesize neopterin. Neopterin is an oxidized form of 7,8-dihydroneopterin, a product
of γ-interferon-mediated upregulation of GTP cyclohydrolase I (GTPCH1) [18]. Therefore, the primary
pterin generated in monocyte-derived macrophages during immune activation is 7,8-dihydroneopterin,
not neopterin. An elevation in tissue and fluid neopterin concentrations are the result of both
immune-activated macrophages, and oxidants reacting with 7,8-dihydroneopterin to generate
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neopterin. The consequence is that the ratio of neopterin to 7,8-dihydroneopterin may differ depending
on the level of immune activation and oxidative environment at sites of inflammation. What we suggest
should be measured clinically is neopterin and total neopterin (the combination of both neopterin
and 7,8-dihydroneopterin) to gain a more accurate measurement of macrophage activity during
inflammation [16]. The concept of measuring neopterin and total neopterin has become forgotten with
the relative ease and convenience of measuring only neopterin. In this short review, we will examine
the cellular biochemistry of 7,8-dihydroneopterin and neopterin to examine the potential additional
benefit of measuring total neopterin as well as neopterin.
2. Synthesis within Macrophages
Interferons α and γ, lipopolysaccharide, and possibly phorbol ester all upregulate the activity of
monocyte-derived macrophage GTPCH1 [19]. GTPCH1 metabolizes GTP to 7,8-dihydroneopterin-
triphosphate, which is then converted to 7,8-dihydroneopterin after dephosphorylation by non-specific
phosphatases (Figure 1) [20]. In non-primate macrophage cells and other non-monocyte derived cells
within the body, the combined enzymatic actions of 6-pyruvoyltetrahydropterin synthase followed
by sepiapterin reductase converts 7,8-dihydroneopterin-triphosphate through to tetrahydrobiopterin,
which is a key cofactor for a number of synthetic enzymes [21]. 7,8-Dihydroneopterin synthesis
predominately occurs in primate macrophages because the expression of 6-pyruvoyltetrahydropterin
synthase is not increased by interferon-γ. Thus, the main product of GTP metabolism by the GTPCH1
pathway becomes cytosolic 7,8-dihydroneopterin during macrophage activation in humans [18,21].
In turn, 7,8-dihydroneopterin and neopterin are readily transported in either direction across the
cell membrane. In cell culture, the addition of 7,8-dihydroneopterin to an incubation media results in
the relatively rapid accumulation of 7,8-dihydroneopterin within the cells [22].
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Figure 1. Formation and oxidation of 7,8-dihydroneopterin. In macrophages, interferon-γ upregulates
the cytosolic enzyme GTP cyclohydrolase-1, which converts GTP to 7,8-dihydroneopterin-triphosphate.
The action of non-specific phosphates generates free 7,8-dihydroneopterin whose oxidation generates
neopterin or 7,8-dihydroxanthopterin depending on the oxidant.
3. Biological Activity of 7,8-Dihydroneopterin
7,8-Dihydroneopterin is a potent radical scavenging and chain-breaking antioxidant, which can
out compete α-tocopherol for the lipid peroxyl radical during low-density lipoprotein (LDL) oxidation,
even though it is water soluble [23]. Peroxyl and hydroxyl radical formation of lipid and protein
hydroperoxides is inhibited by 7,8-dihydroneopterin, as well as the loss of protein thiols and
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glutathione [23–25]. Oxidant and cellular-mediated low-density lipoprotein oxidation is effectively
inhibited by 7,8-dihydroneopterin [26,27]. Both the peroxyl radical and oxidized low-density
lipoprotein (oxLDL) induced cell death in monocytes such as U937 cells, and human monocyte-derived
macrophages are blocked by reducing the intracellular stress and preserving the cellular thiol levels
in the presence of 7,8-dihydroneopterin [28–30]. The protective effects are due to the ability of
7,8-dihydroneopterin to rapidly scavenge the free radicals generated within the cellular environment,
which is supported by reports indicating 7,8-dihydroneopterin scavenging hydroxyl and peroxyl
radicals, HOCl, and possibly superoxide [25,29,31–33]. The product of these reactions is a neutralized
oxidant or radical, due to the donation of electrons from 7,8-dihydroneopterin, and a range of
7,8-dihydroneopterin oxidation products, including neopterin (Figure 1). The reaction with hydroxyl
and peroxyl radicals forms a minimal amount of neopterin, while the major product appears to be
7,8-dihydroxanthopterin [24,34,35]. Neopterin is the predominant product of the HOCl reaction,
although the yield is not 100%, because neopterin also reacts with HOCl to generate non-pterin
products [31,32]. Superoxide scavenging by 7,8-dihydroneopterin appears to generate neopterin
based on cellular studies where NADPH-oxidase (NOX) is actively generating superoxide [29].
Interestingly, neopterin has been shown to inhibit NOX, suggesting a potential feedback loop during
inflammation [36]. The antioxidant activity of 7,8-dihydroneopterin has led to the proposal that it
is generated during macrophage activation with the purpose of self-protection within the highly
oxidizing environment of an inflammatory site [23,37,38].
7,8-Dihydroneopterin, but not neopterin or xanthopterin, downregulates the level of CD36,
which is the primary scavenger receptor responsible for the uptake of oxidized LDL and foam
cell formation in atherosclerosis [29,39]. OxLDL uptake by macrophages via CD36 is unregulated,
leading to the formation of lipid load foam cells within the atherosclerotic plaque. The downregulation
of CD36 decreases oxLDL uptake in macrophages [29], suggesting that 7,8-dihydroneopterin may
regulate to some extent foam cell formation within the artery wall.
Neopterin has been reported to activate inducible nitric oxide synthase (iNOS) in rat smooth
muscle cells [40], but suppress iNOS activation in ovarian carcinoma cells [41], although the
concentrations used were relatively high. 7,8-Dihydroneopterin also appears to have some cytotoxic
effects, which are likely due to it being a strong reducing agent [42–46]. High concentrations of
7,8-dihydroneopterin and neopterin promote apoptosis in a number of cells, although we have
not observed this with monocytes such as human-derived U937 or THP-1 cells, or with human
monocyte-derived macrophages.
The evidence suggests that measuring either neopterin or 7,8-dihydroneopterin alone cannot
provide a complete picture of oxidative stress or immune activation. Rather, the combination of
both biomarkers elucidates a more robust mechanism of the inflammatory process, with an analysis
of neopterin being a measure of the oxidative status within the cells, and 7,8-dihydroneopterin
being a measure of interferon-mediated cellular activation. Moreover, measuring the ratio between
7,8-dihydroneopterin and neopterin may elucidate differences in overall oxidative stress versus
immune activation in different disease models and physical trauma.
4. Measurement of Neopterin and Total Neopterin
Neopterin was first isolated from human urine in 1967 [47] and used as a diagnostic biomarker of
infection and illness [48]. Since then, there has been a plethora of analytical techniques developed and
validated for the quantification of neopterin concentrations in a verity of bodily fluids. Serum and
plasma neopterin are commonly measured to assess immune activation by radioimmuno assay
(RIA), enzyme linked immunosorbent assay (ELISA) [49], or reverse phase high-performance liquid
chromatography (RP-HPLC) coupled with fluorescence detection [50,51]. Levels of neopterin in
urine have largely been quantified using RP-HPLC, in part due to the inaccuracy of RIA when
analyzing urine [52]. However, ELISA is also an accurate tool for urinary neopterin measurement [14].
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Neopterin has been quantified in other mediums including but not limited to, cerebrospinal fluid [53],
cell media [18], and pus [54].
Although ELISA offers high throughput analysis within hospitals, small-scale clinical and research
laboratory analysis have used HPLC. Since neopterin is highly fluorescent, nanomolar concentrations
can be reliably detected after separation from other compounds. C18 has been popular, but we have
found isocratic analysis on strong cation exchange (SCX) columns at pH 2.5 that were excellent for
urine analysis [9,35]. However, for plasma analysis, we have found the amino column-based separation
similarly reliable and efficient [55]. The amino column method was original designed for LC-MS, but
we have found fluorescence detection to be more than adequate for most clinical needs.
Although an abundance of detection methodologies is promising, sample preparation still remains
an important aspect. Since urine contains very low levels of proteins, and HPLC columns have become
relatively inexpensive compared to sample clean-up costs, an HPLC analysis of urine usually involves
the direct injection of diluted urine into the HPLC [9]. In comparison, plasma and cell lysates require
complete protein removal before HPLC analysis. Solid phase extraction has often been used, but this
adds considerable cost to the analysis [56]. Trichloroacetic acid precipitation has often be cited [12],
but we found that significant neopterin is lost with this method when compared to protein precipitation
with 50% acetonitrile [13].
In spite of 7,8-dihydroneopterin’s biosynthetic heritage providing potential for an excellent
marker of immune activation, it has been widely neglected in clinical or experimental research.
7,8-Dihydroneopterin’s low fluorescence and nM concentration in plasma make it relatively difficult to
detect. 7,8-Dihydroneopterin can be easily detected at µM concentration by its absorbance at 254 nm,
but in clinical samples, it is usually at the nM level. There is also no ELISA kit that is commercially
available for 7,8-dihydroneopterin, kits are only available for neopterin. 7,8-Dihydroneopterin is also
both heat and UV light-sensitive in comparison to neopterin [57].
The usual approach to measure 7,8-dihydroneopterin is oxidation to neopterin using an acidic
iodine solution [9,13,58] or manganese dioxide [17]. Therefore, the measurement of neopterin and
7,8-dihydroneopterin requires two injections of the sample: one untreated to measure neopterin,
and the other where 7,8-dihydroneopterin has been oxidized to neopterin. The neopterin detected in
an oxidized sample is a measure of the “total neopterin”, which is the combination of neopterin plus
acidic iodide-oxidized 7,8-dihydroneopterin [9,16]. 7,8-Dihydroneopterin values can be calculated
by subtracting neopterin from total neopterin. A key part of the oxidation methodology is regularly
checking the acidic iodine solution to ensure complete oxidation of 7,8-dihydroneopterin to neopterin,
because the solution does degrade with time.
Another reason that neopterin has been favored over total neopterin analysis is because
7,8-dihydroneopterin can be labile. In air-saturated solution at 25 ◦C, 7% of the 7,8-dihydroneopterin
was lost over 4 h [57]. This rate of loss can be accelerated by UV light. If total neopterin is to be
measured, it is important that samples are collected on ice and protected from UV light as much as
possible. Care is also required to ensure that if samples are transported from a collection point to a site
of analysis, there are tested procedures in place to eliminate the possibility of 7,8-dihydroneopterin
oxidation. Overall, total neopterin analysis is more demanding to carry out than straight neopterin.
The two-step process to measure 7,8-dihydroneopterin can be avoided using HPLC coupled with
mass spectrometry (LC-MS or LC-tandem mass spectrometry (LC-MS/MS)) [55,59]. The sensitivity
of mass spectrometry has urinary neopterin and biopterin detection limits of 0.082 and 0.76 nM,
respectively, which are much lower than fluorescence detection. Moreover, 7,8-dihydroneopterin has
been directly detected and quantified by HPLC-MS, ameliorating the need for the oxidation step and
second injection [59,60].
5. Clinical Effectiveness of Neopterin and Total Neopterin
While neopterin has been measured repeatedly as an assessment of macrophage activation and
infiltration for several decades [5,48,61–63], complete estimation of immune activation through total
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neopterin analysis has limited transparency for clinical outcomes. In 1989, Fuchs et al. [16] measured
neopterin plus 7,8-dihydroneopterin in HIV patients, suggesting that both provide equal potential
for clinical diagnosis. Since 1989, neopterin and total neopterin have been measured selectively in
various illnesses, including chronic renal failure [64] and HIV [61,65], which ultimately limits the
diagnostic potential of neopterin and 7,8-dihydroneopterin as biomarkers due to a lack of specificity
for any particular inflammatory condition. A recent study has measured urinary neopterin and
7,8-dihydroneopterin in patients with the chronic inflammatory disease Duchenne muscular dystrophy
(DMD) [66]. Lindsay et al. [67] measured variable differences in neopterin based on hydration
correction methods, but a significant elevation in 7,8-dihydroneopterin in DMD patients compared
with healthy age-matched controls. Thus, urinary neopterin analysis would have suggested that
DMD patients do not have elevated immune activation, and solidifies the need for neopterin and total
neopterin analysis in a clinical environment.
Recently, neopterin and 7,8-dihydroneopterin have been used as indicators of immune system
activation in sport and exercise medicine, and are gaining momentum over other traditional
inflammatory markers [68]. Their benefits include non-invasive urinary assessment, economical
analysis by HPLC [9], and fast elimination kinetics [7] that offer immediate and cost-effective
analysis; these advantages are pertinent in exercise stress evaluation and athlete management. In a
clinical setting, total neopterin is still under-represented when examining diseases and illnesses of an
inflammatory nature. However, evidence suggests that participants subjected to high intensity and
trauma-inducing exercise stimulate 7,8-dihydroneopterin production, but with varying degrees of its
oxidized form.
Neopterin has been routinely measured in several high-intensity exercise studies. Neopterin
has been shown to rise in response to high-intensity cycling [69], ultra-endurance events [70],
body-building [9], mixed martial arts [8,71,72], and professional rugby [35,73,74], and has shown
promise as an indicator of non-functional overreaching or over-training syndrome [75]. Contrasting
results suggest that its accumulation may be intensity-dependent [76,77], as the impacts and total
running distance during a game of rugby strongly correlate with the observed increase in neopterin
and total neopterin concentration [73]. Recently, neopterin has also been used to assess the positional
demands of professional rugby players [78], and used to evaluate the effectiveness of post-game rugby
union recovery interventions [79], the efficacy of cold water immersion [1–3], stress perturbations
associated with ischemic preconditioning [4], and the monitoring of season-long stress fluctuations in
professional rugby players [5].
Typically, exercise studies have only measured neopterin [6,7]. Whilst neopterin provides
an estimation of immune system activation, research has widely neglected the measurement of
7,8-dihydroneopterin, which is critical for understanding total macrophage activation following
exercise and trauma. The measurement of neopterin alone may simply provide an estimation of the
change in oxidative status of an individual. However, research has observed significant increases in
other inflammatory mediators such as C-reactive protein and TNF-α in conjunction with neopterin
following muscle damaging exercise, albeit at various time points [8].
Recent studies examining impact-induced trauma during exercise have begun to elucidate the
importance of measuring neopterin in addition to 7,8-dihydroneopterin. The combined analysis
provides a comprehensive overview of exercise-induced changes in oxidative status and
immune system activation [35,71,72]. For example, a study measuring changes in neopterin
and 7,8-dihydroneopterin following a mixed martial arts training session has shown that
7,8-dihydroneopterin can dramatically increase without any change in neopterin [8]. There is also
evidence that the ratio of neopterin to total neopterin can range from 20.9–92.1% [9].
Within atherosclerotic plaque, we have observed a section of plaque that contains only
7,8-dihydroneopterin, while other sections only contain neopterin [80]. Moreover, extreme intra
individual and inter individual variation exists in athletes following high-intensity exercise [8,73],
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thus cementing the need for the measurement of both compounds to separate changes in oxidative
status and immune system activation.
To complicate the exercise-related research on neopterin, recent evidence [35,71,72] has identified
a correlation between impact-induced myoglobin release and changes in neopterin concentration.
Hypochlorite, which is produced primarily by neutrophils and macrophages to a lesser extent [81,82],
is capable of oxidizing 7,8-dihydroneopteirn to neopterin in vivo [31,32]. There is also evidence
that superoxide can also oxidize 7,8-dihydroneopterin to neopterin, as the addition of apocynin to
macrophages inhibits the oxidation of 7,8-dihydroneopterin to neopterin [29]. The in vitro and in vivo
oxidation of 7,8-dihydroneopterin to neopterin by myoglobin verifies its previously identified oxidative
potential [83,84]. This suggests that muscle-damaging exercise resulting in the release of intracellular
constituents may exacerbate oxidative stress (neopterin), resulting in significant elevations that may
not be directly related to the acute phase response. This further substantiates the necessity of neopterin
and 7,8-dihydroneopterin measurement for separating and accurately disseminating oxidative stress
and inflammation-related exercise research.
6. Conclusions
Collectively, sport and exercise research that have measured neopterin and 7,8-dihydroneopterin
have provided evidence that the change in one does not necessarily result in a change in the
other. To critically and correctly evaluate a clinical outcome, treatment efficacy, or the oxidative
status/immune system activation of an individual, neopterin and 7,8-dihydroneopterin should
be simultaneously measured. There is a clear need to bring the analysis of neopterin and
7,8-dihydroneopterin from sport and exercise medicine back into the classical clinical environment.
The measurement of neopterin and total neopterin would provide a clearer and more sensitive measure
of patient oxidative stress and inflammation during clinical events.
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